Influenza B virus (IBV) stands as a paradox, often overshadowed by its more notorious counterpart, influenza A virus (IAV). Yet, it remains a captivating and elusive subject of scientific inquiry.
The anti-infective drug market is seeing strong growth due to multiple interrelated factors. One key driver is the rising incidence of specific infectious diseases, including healthcare-associated ...
Background: The efficacy and tolerability of the neuraminidase inhibitor zanamivir in the treatment of influenza have been established in an extensive programme of controlled clinical trials.